纳米药物劫持血液转移素用于铁中介癌症治疗
Shuyue Zhang1, Xiao Wu1, Xiaoming Liao1
1College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 610064 Chengdu, China.
Journal of the American Chemical Society
|March 15, 2024
概括
这项研究引入了一种新的铁补充纳米药物 (T10@cLAV),该药物向瘤细胞,以提高铁亡的铁含量,这是一种有前途的癌症治疗方法. 这种纳米药物在小鼠中表现出有效的瘤抑制,没有观察到毒性.
科学领域:
- 生物医学工程
- 纳米技术
- 癌症治疗方法
背景情况:
- 是一种有前途的癌症治疗策略.
- 有效的癌症治疗需要精确控制细胞内铁含量.
- 目前的铁补充策略面临的局限性包括铁素含量低或铁基材料的不良影响.
研究的目的:
- 开发一种新的铁补充纳米药物,
- 通过增加细胞内铁含量来增强ferroptosis的诱导.
- 在临床前癌症模型中评估开发的纳米药物的疗效和安全性.
主要方法:
- 在交联的脂肪酸囊泡 (T10@cLAV) 上结合转移林化T10.
- 使用T10@cLAV劫持血液转移蛋白 (Tf) 进行特定的瘤细胞输送.
- 评估瘤细胞内二酸的Fe2+再生.
- 在具有HeLa瘤的裸体小鼠模型中评估瘤抑制和毒性.
主要成果:
- T10@cLAV成功地将铁输送到瘤细胞,从而提高了细胞内Fe2+水平.
- 这种纳米药物促进了铁,导致显著的瘤抑制.
- 通过T10@cLAV的瘤抑制与低剂量 (5 mg/ kg) 的西斯普拉丁相当.
- 在高达300mg/kg的剂量下,T10@cLAV没有表现出毒性.
结论:
- 这种T10@cLAV纳米药物代表了在癌症治疗中补充铁的新有效策略.
- 通过劫持血液转移蛋白来提供向的铁, 与现有方法相比,
- 这种方法显示出基于铁的安全有效癌症治疗的潜力.
相关概念视频
01:16Necrosis
4.5K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.5K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K